Evidence map›Paper›PMID 36810809›Full record

ArticleObesity surgery2023

Analysis of Reported Adverse Events Associated with Over-the-Scope Endoscopic Suturing System: an FDA MAUDE Database Study.

Natalie Wilson, Mohamed Abdallah, Fouad Jaber, Willie Mohammed Johnson, Nicholas McDonald, Michelle Baliss, Shailendra Singh, Mohammad Bilal

Abstract read
PubMed Publisher
In one paragraph

Article in Obesity surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Update on Endoscopic Treatments for Obesity.Current obesity reports · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Natalie WilsonDepartment of Internal Medicine, University of Minnesota, Minneapolis, MN, 55455, USA.ORCID http://orcid.org/0000-0003-1648-3310
Mohamed AbdallahDivision of Gastroenterology and Hepatology, University of Minnesota, Minneapolis, MN, 55455, USA.
Fouad JaberDepartment of Internal Medicine, University of Missouri-Kansas City, Kansas City, MO, 64110, USA.
Willie Mohammed JohnsonDepartment of Internal Medicine, University of Minnesota, Minneapolis, MN, 55455, USA.
Nicholas McDonaldDivision of Gastroenterology and Hepatology, University of Minnesota, Minneapolis, MN, 55455, USA.
Michelle BalissDivision of Gastroenterology and Hepatology, St. Louis University, St. Louis, MO, 63110, USA.
Shailendra SinghDivision of Gastroenterology and Hepatology, West Virginia University, Morgantown, WV, 26506, USA.
Mohammad BilalDivision of Gastroenterology and Hepatology, University of Minnesota, Minneapolis, MN, 55455, USA. billa17@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe over-the-scope endoscopic suturing system (ESS) (OverStitch™) is one of the most widely utilized endoscopic suturing systems in current clinical practice; however, data on the adverse events associated with this device is scarce. Our study aims to evaluate the adverse events and complications associated with the over-the-scope ESS using the FDA's Manufacturer and User Facility Device Experience (MAUDE) database. MATERIALS AND

methodsWe analyzed the post-marketing surveillance data from the FDA MAUDE database for the over-the-scope ESS from January 2008 through June 2022.

resultsEighty-three reports were filed from January 2008 to June 2022. Adverse events were classified as device-related complications and patient-related adverse events. Seventy-seven device-related issues and 87 patient adverse events were identified. The most common device-related issue was difficulty to remove after deployment (n=12, 15.58%) followed by mechanical problem (n=10, 12.99%), mechanical jam (n=9, 11.69%), or entrapment of device (n=9, 11.69%). Of the 87 patient-related adverse events, the most common was perforation (n=19; 21.84%), followed by device embedded in tissue or plaque (n=10; 11.49%), and abdominal pain (n=8; 9.20%). Of the 19 patients who experienced perforation, two required open surgical repair and one required laparoscopic surgical repair.

conclusionThe overall adverse events from the over-the-scope ESS remain acceptable as evidenced by the number of reported cases since 2008. However, it is important to note that adverse event rates might increase as the use of the device increases; therefore, it is essential for endoscopists to be aware of the potential common and rare adverse events associated with the use of the over-the-scope ESS device.

Indexed as

LaparoscopyObesity, MorbidDatabases, FactualHumansUnited StatesAdverse eventsEndoscopic closureEndoscopic suturing systemMAUDE database

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.